National Institutes of Health

Resvita Bio is engaged in the development and manufacturing of engineered probiotics aimed at treating skin-related diseases, including chronic conditions and cancer. The company focuses on creating a versatile skin microbial platform utilizing synthetic biology and metabolic engineering. This innovative approach allows for the continuous delivery of therapies that alleviate inflammation, promote tissue regeneration, and eliminate harmful bacteria. By leveraging this technology, Resvita Bio aims to offer faster and more efficient treatment alternatives for individuals suffering from chronic skin diseases.

Phase provides 3D-printing medical devices for microfluidics. Phase’s proprietary platform enables PDMS (Sylgard 184) to be 3D printed at a scale and resolution that was previously unattainable.

Clene Nanomedicine Inc. is a clinical-stage biopharmaceutical company based in Salt Lake City, Utah, that specializes in developing innovative therapeutics for neurodegenerative diseases and other conditions with unmet medical needs. The company has created a novel drug platform known as Clean-Surface Nanosuspension, which enables the production of clean-surface nanocrystal medicines. This technology supports a pipeline of new drug candidates, particularly targeting demyelinating disorders and oncology. Founded in 2012, Clene Nanomedicine aims to advance treatment options through its unique approach to drug development.

Aphios Corporation is a biotechnology company based in Woburn, Massachusetts, specializing in drug delivery and manufacturing technologies. Founded in 1993, Aphios develops innovative platforms that enhance drug discovery and ensure the safety of pharmaceuticals. The company focuses on creating therapeutic products aimed at health maintenance, disease prevention, and treatment of various conditions, including cancers, infectious diseases, and central nervous system disorders. Notable products include Zindol, a ginger-derived therapeutic, and several advanced formulations such as APH-0703, a protein kinase C activator, and APH-0911, a nanotechnology-based prodrug for cancer treatment. Additionally, Aphios is engaged in developing technologies related to supercritical fluids for the production of natural pharmaceuticals, as well as specialized equipment for various applications, including microbial cell disruption and biomass pretreatment for biofuels. The company also provides virology testing services to validate viral clearance and inactivation.

Chemeleon has developed an innovative diagnostic platform that provides rapid, accurate, and affordable detection of a wide array of analytes, including drugs, proteins, and viruses. This proprietary in vitro diagnostic technology delivers a colorimetric readout within minutes, visible to the naked eye, without requiring reagents, instruments, or specialized training. This capability facilitates decentralized testing, allowing clinicians to extend point-of-care diagnostics and enabling individuals to self-administer tests at the point of need. By combining selective molecular receptors with colorimetric nanomaterial reporters, Chemeleon's diagnostics offer immediate and actionable results, significantly improving patient outcomes while reducing costs. Notably, under a National Institutes of Health grant, the company created a test to detect beta-2-transferrin, aiding healthcare providers in promptly diagnosing cerebrospinal fluid leaks, which can drastically lower morbidity and patient stay duration. This technology meets the World Health Organization's ASSURED criteria, making it suitable for both advanced healthcare settings and resource-limited environments, thereby revolutionizing the accessibility of critical diagnostic services.

Matregenix is a MedTech company offering advanced nanofibrous materials for medical applications. MatriNova, the first application of the platform technology is a barrier membrane with characteristics for use in periodontal surgeries. Matregenix, Inc. was founded in 2018 by Sherif Soliman and is based in Irvine, California.

Phase provides 3D-printing medical devices for microfluidics. Phase’s proprietary platform enables PDMS (Sylgard 184) to be 3D printed at a scale and resolution that was previously unattainable.

Partillion Bioscience is an early-stage life science company focused on developing a functional single-cell analysis platform. This innovative platform utilizes a novel nano vial technology to rapidly compartmentalize and analyze millions of single cells, specifically targeting secreted proteins. By enabling detailed examination of biological functions, Partillion aims to democratize advanced single-cell assays for biotech laboratories and clients. This capability supports the development of more effective therapies for various conditions, including cancer, autoimmune diseases, and infectious diseases.

Cytonus Therapeutics, Inc. is a biotechnology company founded in 2018 and based in Columbus, Ohio. The company focuses on developing immune-oncology and gene therapies aimed at treating devastating and rare diseases. Cytonus combines artificial intelligence-driven drug discovery with a unique delivery system known as Cargocyte, which utilizes synthetic biology for precision treatment. The company's mission centers on addressing immune-related disorders through innovative approaches that enable targeted delivery and in vivo production of first-in-class therapeutics.

Partillion Bioscience is an early-stage life science company focused on developing a functional single-cell analysis platform. This innovative platform utilizes a novel nano vial technology to rapidly compartmentalize and analyze millions of single cells, specifically targeting secreted proteins. By enabling detailed examination of biological functions, Partillion aims to democratize advanced single-cell assays for biotech laboratories and clients. This capability supports the development of more effective therapies for various conditions, including cancer, autoimmune diseases, and infectious diseases.

Partillion Bioscience is an early-stage life science company focused on developing a functional single-cell analysis platform. This innovative platform utilizes a novel nano vial technology to rapidly compartmentalize and analyze millions of single cells, specifically targeting secreted proteins. By enabling detailed examination of biological functions, Partillion aims to democratize advanced single-cell assays for biotech laboratories and clients. This capability supports the development of more effective therapies for various conditions, including cancer, autoimmune diseases, and infectious diseases.

Ceres Nanosciences Inc. is a privately held life sciences company focused on the development and commercialization of innovative sample preparation products utilizing its proprietary Nanotrap® technology. This technology captures, enriches, and preserves analytes and biomarkers, which is essential for the early detection of diseases such as cancer, cardiac conditions, and infectious diseases. By facilitating the identification of low abundance biomarkers, Ceres aims to enhance diagnostic accuracy and improve patient outcomes while potentially reducing healthcare costs. The company has a diverse product pipeline that includes advanced sample collection technologies and diagnostics, supported by federal grants and industry collaborations. Among its key developments is a direct antigen test for Lyme disease, which is anticipated to be available for commercial use.

Cytonus Therapeutics, Inc. is a biotechnology company founded in 2018 and based in Columbus, Ohio. The company focuses on developing immune-oncology and gene therapies aimed at treating devastating and rare diseases. Cytonus combines artificial intelligence-driven drug discovery with a unique delivery system known as Cargocyte, which utilizes synthetic biology for precision treatment. The company's mission centers on addressing immune-related disorders through innovative approaches that enable targeted delivery and in vivo production of first-in-class therapeutics.

Cytonus Therapeutics, Inc. is a biotechnology company founded in 2018 and based in Columbus, Ohio. The company focuses on developing immune-oncology and gene therapies aimed at treating devastating and rare diseases. Cytonus combines artificial intelligence-driven drug discovery with a unique delivery system known as Cargocyte, which utilizes synthetic biology for precision treatment. The company's mission centers on addressing immune-related disorders through innovative approaches that enable targeted delivery and in vivo production of first-in-class therapeutics.

Cytonus Therapeutics, Inc. is a biotechnology company founded in 2018 and based in Columbus, Ohio. The company focuses on developing immune-oncology and gene therapies aimed at treating devastating and rare diseases. Cytonus combines artificial intelligence-driven drug discovery with a unique delivery system known as Cargocyte, which utilizes synthetic biology for precision treatment. The company's mission centers on addressing immune-related disorders through innovative approaches that enable targeted delivery and in vivo production of first-in-class therapeutics.

Viewpoint Molecular Targeting develops radiopharmaceutical therapeutics for cancer and complementary diagnostic imaging agents that enable a personalized approach to cancer therapy. ViewpointMT's alpha-particle radiotherapies deliver alpha radiation specifically to cancer cells utilizing specialized targeting peptides. ViewpointMT is also developing complementary diagnostics that utilize the same targeting peptide which provide the opportunity to personalize treatment and optimize patient outcomes. This "theranostic” approach enables the ability to see the specific tumor and then treat it to potentially improve efficacy and minimize toxicity associated with many other types of cancer treatments.

Ceres Nanosciences Inc. is a privately held life sciences company focused on the development and commercialization of innovative sample preparation products utilizing its proprietary Nanotrap® technology. This technology captures, enriches, and preserves analytes and biomarkers, which is essential for the early detection of diseases such as cancer, cardiac conditions, and infectious diseases. By facilitating the identification of low abundance biomarkers, Ceres aims to enhance diagnostic accuracy and improve patient outcomes while potentially reducing healthcare costs. The company has a diverse product pipeline that includes advanced sample collection technologies and diagnostics, supported by federal grants and industry collaborations. Among its key developments is a direct antigen test for Lyme disease, which is anticipated to be available for commercial use.

NanoScope Technologies was founded in 2009 with an objective to develop new methods and devices for scientific, industrial and biomedical applications. Nanoscope has developed a range of biomedical technologies which include diagnostics and therapeutic devices and molecules. These have already generated interest from several clinicians, industries and leaders. We strive to translate the technology to market and bedside.

Cytonus Therapeutics, Inc. is a biotechnology company founded in 2018 and based in Columbus, Ohio. The company focuses on developing immune-oncology and gene therapies aimed at treating devastating and rare diseases. Cytonus combines artificial intelligence-driven drug discovery with a unique delivery system known as Cargocyte, which utilizes synthetic biology for precision treatment. The company's mission centers on addressing immune-related disorders through innovative approaches that enable targeted delivery and in vivo production of first-in-class therapeutics.

Ceres Nanosciences Inc. is a privately held life sciences company focused on the development and commercialization of innovative sample preparation products utilizing its proprietary Nanotrap® technology. This technology captures, enriches, and preserves analytes and biomarkers, which is essential for the early detection of diseases such as cancer, cardiac conditions, and infectious diseases. By facilitating the identification of low abundance biomarkers, Ceres aims to enhance diagnostic accuracy and improve patient outcomes while potentially reducing healthcare costs. The company has a diverse product pipeline that includes advanced sample collection technologies and diagnostics, supported by federal grants and industry collaborations. Among its key developments is a direct antigen test for Lyme disease, which is anticipated to be available for commercial use.

POP Biotechnologies is a life sciences company based in Buffalo, NY, focused on enhancing individual health through innovative nanomedicine solutions. The company develops targeted therapies aimed at treating cancer and other serious diseases, utilizing advanced nanoparticle-based drug delivery systems. Their proprietary technology allows for the precise release of drug payloads when activated by near-infrared light, providing healthcare providers with effective tools to address patient needs in oncology and infectious diseases.

The Cornell High Energy Synchrotron Source is a science and technology laboratory. They assist in the development of equipment that supports research and experiments. They will make undulator beamtime available for certain user groups to create new tools, processes, and synchrotron radiation applications. They provide resources for physics, chemistry, biology, environmental science, and materials science research.

Viewpoint Molecular Targeting develops radiopharmaceutical therapeutics for cancer and complementary diagnostic imaging agents that enable a personalized approach to cancer therapy. ViewpointMT's alpha-particle radiotherapies deliver alpha radiation specifically to cancer cells utilizing specialized targeting peptides. ViewpointMT is also developing complementary diagnostics that utilize the same targeting peptide which provide the opportunity to personalize treatment and optimize patient outcomes. This "theranostic” approach enables the ability to see the specific tumor and then treat it to potentially improve efficacy and minimize toxicity associated with many other types of cancer treatments.

Versatope is an immuno-therapeutic company that uses a biotechnology platform to delivery immunity. The company develops a bacterial factory nano particle technology and multiple epitopes can be displayed to overcome strain-specific immunity, enabling biotechnology companies to develop a single vaccine to protect against multiple strains of influenza.

NanoScope Technologies was founded in 2009 with an objective to develop new methods and devices for scientific, industrial and biomedical applications. Nanoscope has developed a range of biomedical technologies which include diagnostics and therapeutic devices and molecules. These have already generated interest from several clinicians, industries and leaders. We strive to translate the technology to market and bedside.

Ossium Health, Inc. is engaged in the development and manufacturing of cell therapy products aimed at treating leukemia, other blood cancers, and tissue damage, as well as addressing radiation poisoning. The company offers a range of innovative therapies, including HPC, Marrow, which features HLA-matched bone marrow stem cells for hematopoietic reconstitution in blood cancer patients; Chimera, which enhances organ transplantation; and Chymalis, composed of mesenchymal stem cells that promote the healing of damaged bone and muscle tissue. Additionally, Ossium provides bone marrow cells for research purposes in oncology and immunology. Founded in 2016 and headquartered in San Francisco, California, Ossium Health focuses on improving health outcomes and longevity through advanced bioengineering techniques.